Business
Topline Results From Phase 2 Celia Study Of Diranersen (Biib080): First Study To Show Reduction In Tau Pathology And Cognitive Benefit In Patients With Early Alzheimer’s Disease
By Biogen
CELIA did not meet its primary endpoint assessing dose response; based on the strength of the biomarker and efficacy data, Biogen plans to advance diranersen to registrational development
Robust reductions in tau pathology were observed across all st ...Read more
